Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$17.81
-0.4%
$19.99
$10.21
$25.67
$4.27B0.433.68 million shs1.92 million shs
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$50.37
-2.2%
$49.21
$21.34
$58.40
$4.11B-0.151.05 million shs794,299 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$108.41
+0.8%
$106.61
$72.21
$139.13
$5.29B0.46665,005 shs622,917 shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$15.30
+4.8%
$16.53
$7.93
$25.29
$1.30B0.721.61 million shs1.43 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
-0.39%-0.39%-13.59%-8.15%+53.01%
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-2.23%-2.02%-7.20%+34.82%+126.99%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+0.85%+5.28%-3.13%+6.63%+29.65%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+4.79%+4.01%-0.13%+6.62%+75.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.1295 of 5 stars
3.72.00.00.02.92.53.1
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.4454 of 5 stars
3.51.00.04.71.30.80.0
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.7367 of 5 stars
4.51.00.04.52.44.20.6
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
3.3195 of 5 stars
4.43.00.00.02.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6755.34% Upside
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$82.5063.79% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.06
Buy$172.3358.96% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.14110.08% Upside

Current Analyst Ratings Breakdown

Latest TVTX, AXSM, AKRO, and ADMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$190.00
7/1/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$30.00
6/12/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$30.00
6/11/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$35.00 ➝ $32.00
6/10/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00
6/9/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$153.00 ➝ $150.00
6/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$185.00
5/27/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$63.00 ➝ $64.00
5/22/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
5/16/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M9.97$0.54 per share33.03$1.48 per share12.03
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M13.84N/AN/A$1.18 per share91.87
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M5.83N/AN/A$0.76 per share20.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8520.9525.81N/A45.01%47.16%30.51%8/6/2025 (Estimated)
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.77N/A38.44N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.81N/AN/AN/A-82.88%-1,179.73%-41.10%7/30/2025 (Estimated)

Latest TVTX, AXSM, AKRO, and ADMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.04N/AN/AN/A$140.02 millionN/A
5/12/2025Q1 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$1.01$0.90+$1.91$0.90N/AN/A
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
5/1/2025Q1 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.03
16.80
16.80
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.48
2.03
1.96
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.46
2.05
2.03

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.70%
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.40%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million229.90 millionOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.72 million74.08 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.24 million38.21 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46088.81 million85.20 millionOptionable

Recent News About These Companies

Q2 EPS Estimate for Travere Therapeutics Lowered by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$17.81 -0.07 (-0.39%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$17.86 +0.05 (+0.28%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$50.37 -1.15 (-2.23%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$50.38 +0.01 (+0.01%)
As of 07:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$108.41 +0.91 (+0.85%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$108.65 +0.24 (+0.22%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$15.30 +0.70 (+4.79%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$15.20 -0.10 (-0.65%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.